CARAT consortium enjoying some late summer days in Milan, Italy

1st CARAT Progress Meeting

Nine months into the project and with the 1st project interim report around the corner, the CARAT consortium gathered together on September 29-30, 2016 for their 1st Progress Meeting. The meeting was hosted by CARAT’s Italian partner Ospedale San Raffaele (OSR) in Milan, Italy, the perfect location to enjoy some last late summer days before fall.

The meeting started off with a set of progress sessions relating to the five technical Work Packages in the project. Each Work Package leader presented the work done since the project’s Kick-off Meeting and the next steps to be taken. Lively discussions ensued during the presentations, covering inter alia the subject of appropriate protocols, establishment of a CAR sharing platform and improvement of technologies.

In the afternoon, Eurice encouraged the partners to give exploitation issues some very first considerations during a 2-hour exploitation workshop. After an introductory talk, the participants split up in three groups to discuss pre-defined key exploitable results deriving from the project. They filled out a questionnaire which was presented to the other participants at the end of the workshop. All in all, the workshop reached its goal of raising awareness about the importance of exploiting CARAT results and the work done will be followed up in subsequent sessions at the next meetings.

The day closed with a short virtual tour through the hospital given by OSR’s Deputy Scientific Director Prof. Luca Guidotti and OSR’s Principal Investigator in CARAT, Attilio Bondanza, showing interested participants the lab and the campus.

After an enjoyable Italian dinner with the entire consortium, the partners met refreshed on the next day to discuss general issues regarding regulatory aspects and dissemination of CARAT results. The largest part of the morning session was dedicated to group work where the partners split up in smaller groups to precisely prepare the next steps in the individual Work Packages.

In the upcoming months, the consortium will intensify their efforts in making preparations towards the final goal of CARAT, i.e. the setup of an automated, cost-efficient and ready-to-use manufacture of effective CAR-modified T cells for personalized cell therapy (“CARAT platform”).

Further reading
Carat
Life Sciences, Food & Biotech
CARAT
Chimeric Antigen Receptors (CARs) for Advanced Therapies
Your Contact
Jj
Janine Jost
Senior Project Manager
Phone: +49 6894 3881331

Tags: Horizon 2020